PMC:7035340 / 2831-4000 JSON TXT

Annnotations TAB JSON ListView MergeView

LitCovid-PubTator

LitCovid-PD-FMA-UBERON

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T3","span":{"begin":186,"end":190},"obj":"Body_part"}],"attributes":[{"id":"A3","pred":"fma_id","subj":"T3","obj":"http://purl.org/sig/ont/fma/fma7195"}],"text":"Of note, as documented in a series of randomized clinical trials (RCT), low or physiologic dose of corticosteroids treatment did not reduce mortality from septic shock caused by primary lung infections, but it could bring clinical benefits to secondary outcomes, such as earlier reversal of shock, shorter duration to exit from ICU and mechanical ventilation9,10. Besides, salvage corticosteroids treatment for severe patients with advanced ARDS could alleviate the pulmonary fibrosis and prevent progressive pathological deterioration11, which provides a good framework for explaining why some critical patients with SARS infection benefit from rescue corticosteroids therapy. More importantly, mortality benefit favored the severe HIN1-illness in the adjunctive treatment group with low dose of corticosteroids12. Evidently, all these results strongly suggest that proper use of low-dose corticosteroids may bring survival advantages for critically ill patients with 2019-nCoV, but this treatment should be strictly performed on NCP patients with definite clinical indications (such as refractory ARDS, sepsis or septic shock) according to the recommended guidelines."}

LitCovid-PD-UBERON

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T2","span":{"begin":186,"end":190},"obj":"Body_part"}],"attributes":[{"id":"A2","pred":"uberon_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/UBERON_0002048"}],"text":"Of note, as documented in a series of randomized clinical trials (RCT), low or physiologic dose of corticosteroids treatment did not reduce mortality from septic shock caused by primary lung infections, but it could bring clinical benefits to secondary outcomes, such as earlier reversal of shock, shorter duration to exit from ICU and mechanical ventilation9,10. Besides, salvage corticosteroids treatment for severe patients with advanced ARDS could alleviate the pulmonary fibrosis and prevent progressive pathological deterioration11, which provides a good framework for explaining why some critical patients with SARS infection benefit from rescue corticosteroids therapy. More importantly, mortality benefit favored the severe HIN1-illness in the adjunctive treatment group with low dose of corticosteroids12. Evidently, all these results strongly suggest that proper use of low-dose corticosteroids may bring survival advantages for critically ill patients with 2019-nCoV, but this treatment should be strictly performed on NCP patients with definite clinical indications (such as refractory ARDS, sepsis or septic shock) according to the recommended guidelines."}

LitCovid-PD-MONDO

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T19","span":{"begin":191,"end":201},"obj":"Disease"},{"id":"T20","span":{"begin":441,"end":445},"obj":"Disease"},{"id":"T21","span":{"begin":466,"end":484},"obj":"Disease"},{"id":"T22","span":{"begin":618,"end":622},"obj":"Disease"},{"id":"T23","span":{"begin":623,"end":632},"obj":"Disease"},{"id":"T24","span":{"begin":1099,"end":1103},"obj":"Disease"}],"attributes":[{"id":"A19","pred":"mondo_id","subj":"T19","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A20","pred":"mondo_id","subj":"T20","obj":"http://purl.obolibrary.org/obo/MONDO_0006502"},{"id":"A21","pred":"mondo_id","subj":"T21","obj":"http://purl.obolibrary.org/obo/MONDO_0002771"},{"id":"A22","pred":"mondo_id","subj":"T22","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A23","pred":"mondo_id","subj":"T23","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A24","pred":"mondo_id","subj":"T24","obj":"http://purl.obolibrary.org/obo/MONDO_0006502"}],"text":"Of note, as documented in a series of randomized clinical trials (RCT), low or physiologic dose of corticosteroids treatment did not reduce mortality from septic shock caused by primary lung infections, but it could bring clinical benefits to secondary outcomes, such as earlier reversal of shock, shorter duration to exit from ICU and mechanical ventilation9,10. Besides, salvage corticosteroids treatment for severe patients with advanced ARDS could alleviate the pulmonary fibrosis and prevent progressive pathological deterioration11, which provides a good framework for explaining why some critical patients with SARS infection benefit from rescue corticosteroids therapy. More importantly, mortality benefit favored the severe HIN1-illness in the adjunctive treatment group with low dose of corticosteroids12. Evidently, all these results strongly suggest that proper use of low-dose corticosteroids may bring survival advantages for critically ill patients with 2019-nCoV, but this treatment should be strictly performed on NCP patients with definite clinical indications (such as refractory ARDS, sepsis or septic shock) according to the recommended guidelines."}

LitCovid-PD-CLO

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T7","span":{"begin":26,"end":27},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T8","span":{"begin":186,"end":190},"obj":"http://purl.obolibrary.org/obo/UBERON_0002048"},{"id":"T9","span":{"begin":186,"end":190},"obj":"http://www.ebi.ac.uk/efo/EFO_0000934"},{"id":"T10","span":{"begin":554,"end":555},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"Of note, as documented in a series of randomized clinical trials (RCT), low or physiologic dose of corticosteroids treatment did not reduce mortality from septic shock caused by primary lung infections, but it could bring clinical benefits to secondary outcomes, such as earlier reversal of shock, shorter duration to exit from ICU and mechanical ventilation9,10. Besides, salvage corticosteroids treatment for severe patients with advanced ARDS could alleviate the pulmonary fibrosis and prevent progressive pathological deterioration11, which provides a good framework for explaining why some critical patients with SARS infection benefit from rescue corticosteroids therapy. More importantly, mortality benefit favored the severe HIN1-illness in the adjunctive treatment group with low dose of corticosteroids12. Evidently, all these results strongly suggest that proper use of low-dose corticosteroids may bring survival advantages for critically ill patients with 2019-nCoV, but this treatment should be strictly performed on NCP patients with definite clinical indications (such as refractory ARDS, sepsis or septic shock) according to the recommended guidelines."}

LitCovid-PD-CHEBI

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T13","span":{"begin":99,"end":114},"obj":"Chemical"},{"id":"T14","span":{"begin":381,"end":396},"obj":"Chemical"},{"id":"T15","span":{"begin":653,"end":668},"obj":"Chemical"},{"id":"T16","span":{"begin":774,"end":779},"obj":"Chemical"},{"id":"T17","span":{"begin":890,"end":905},"obj":"Chemical"}],"attributes":[{"id":"A13","pred":"chebi_id","subj":"T13","obj":"http://purl.obolibrary.org/obo/CHEBI_50858"},{"id":"A14","pred":"chebi_id","subj":"T14","obj":"http://purl.obolibrary.org/obo/CHEBI_50858"},{"id":"A15","pred":"chebi_id","subj":"T15","obj":"http://purl.obolibrary.org/obo/CHEBI_50858"},{"id":"A16","pred":"chebi_id","subj":"T16","obj":"http://purl.obolibrary.org/obo/CHEBI_24433"},{"id":"A17","pred":"chebi_id","subj":"T17","obj":"http://purl.obolibrary.org/obo/CHEBI_50858"}],"text":"Of note, as documented in a series of randomized clinical trials (RCT), low or physiologic dose of corticosteroids treatment did not reduce mortality from septic shock caused by primary lung infections, but it could bring clinical benefits to secondary outcomes, such as earlier reversal of shock, shorter duration to exit from ICU and mechanical ventilation9,10. Besides, salvage corticosteroids treatment for severe patients with advanced ARDS could alleviate the pulmonary fibrosis and prevent progressive pathological deterioration11, which provides a good framework for explaining why some critical patients with SARS infection benefit from rescue corticosteroids therapy. More importantly, mortality benefit favored the severe HIN1-illness in the adjunctive treatment group with low dose of corticosteroids12. Evidently, all these results strongly suggest that proper use of low-dose corticosteroids may bring survival advantages for critically ill patients with 2019-nCoV, but this treatment should be strictly performed on NCP patients with definite clinical indications (such as refractory ARDS, sepsis or septic shock) according to the recommended guidelines."}

LitCovid-PD-HP

{"project":"LitCovid-PD-HP","denotations":[{"id":"T7","span":{"begin":162,"end":167},"obj":"Phenotype"},{"id":"T8","span":{"begin":291,"end":296},"obj":"Phenotype"},{"id":"T9","span":{"begin":466,"end":484},"obj":"Phenotype"},{"id":"T10","span":{"begin":1105,"end":1111},"obj":"Phenotype"},{"id":"T11","span":{"begin":1122,"end":1127},"obj":"Phenotype"}],"attributes":[{"id":"A7","pred":"hp_id","subj":"T7","obj":"http://purl.obolibrary.org/obo/HP_0031273"},{"id":"A8","pred":"hp_id","subj":"T8","obj":"http://purl.obolibrary.org/obo/HP_0031273"},{"id":"A9","pred":"hp_id","subj":"T9","obj":"http://purl.obolibrary.org/obo/HP_0002206"},{"id":"A10","pred":"hp_id","subj":"T10","obj":"http://purl.obolibrary.org/obo/HP_0100806"},{"id":"A11","pred":"hp_id","subj":"T11","obj":"http://purl.obolibrary.org/obo/HP_0031273"}],"text":"Of note, as documented in a series of randomized clinical trials (RCT), low or physiologic dose of corticosteroids treatment did not reduce mortality from septic shock caused by primary lung infections, but it could bring clinical benefits to secondary outcomes, such as earlier reversal of shock, shorter duration to exit from ICU and mechanical ventilation9,10. Besides, salvage corticosteroids treatment for severe patients with advanced ARDS could alleviate the pulmonary fibrosis and prevent progressive pathological deterioration11, which provides a good framework for explaining why some critical patients with SARS infection benefit from rescue corticosteroids therapy. More importantly, mortality benefit favored the severe HIN1-illness in the adjunctive treatment group with low dose of corticosteroids12. Evidently, all these results strongly suggest that proper use of low-dose corticosteroids may bring survival advantages for critically ill patients with 2019-nCoV, but this treatment should be strictly performed on NCP patients with definite clinical indications (such as refractory ARDS, sepsis or septic shock) according to the recommended guidelines."}

LitCovid-sentences

{"project":"LitCovid-sentences","denotations":[{"id":"T18","span":{"begin":0,"end":363},"obj":"Sentence"},{"id":"T19","span":{"begin":364,"end":677},"obj":"Sentence"},{"id":"T20","span":{"begin":678,"end":815},"obj":"Sentence"},{"id":"T21","span":{"begin":816,"end":1169},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Of note, as documented in a series of randomized clinical trials (RCT), low or physiologic dose of corticosteroids treatment did not reduce mortality from septic shock caused by primary lung infections, but it could bring clinical benefits to secondary outcomes, such as earlier reversal of shock, shorter duration to exit from ICU and mechanical ventilation9,10. Besides, salvage corticosteroids treatment for severe patients with advanced ARDS could alleviate the pulmonary fibrosis and prevent progressive pathological deterioration11, which provides a good framework for explaining why some critical patients with SARS infection benefit from rescue corticosteroids therapy. More importantly, mortality benefit favored the severe HIN1-illness in the adjunctive treatment group with low dose of corticosteroids12. Evidently, all these results strongly suggest that proper use of low-dose corticosteroids may bring survival advantages for critically ill patients with 2019-nCoV, but this treatment should be strictly performed on NCP patients with definite clinical indications (such as refractory ARDS, sepsis or septic shock) according to the recommended guidelines."}

2_test

{"project":"2_test","denotations":[{"id":"32296012-29849191-139944474","span":{"begin":358,"end":359},"obj":"29849191"},{"id":"32296012-28098591-139944475","span":{"begin":360,"end":362},"obj":"28098591"},{"id":"32296012-7492007-139944476","span":{"begin":535,"end":537},"obj":"7492007"},{"id":"32296012-28464462-139944477","span":{"begin":812,"end":814},"obj":"28464462"}],"text":"Of note, as documented in a series of randomized clinical trials (RCT), low or physiologic dose of corticosteroids treatment did not reduce mortality from septic shock caused by primary lung infections, but it could bring clinical benefits to secondary outcomes, such as earlier reversal of shock, shorter duration to exit from ICU and mechanical ventilation9,10. Besides, salvage corticosteroids treatment for severe patients with advanced ARDS could alleviate the pulmonary fibrosis and prevent progressive pathological deterioration11, which provides a good framework for explaining why some critical patients with SARS infection benefit from rescue corticosteroids therapy. More importantly, mortality benefit favored the severe HIN1-illness in the adjunctive treatment group with low dose of corticosteroids12. Evidently, all these results strongly suggest that proper use of low-dose corticosteroids may bring survival advantages for critically ill patients with 2019-nCoV, but this treatment should be strictly performed on NCP patients with definite clinical indications (such as refractory ARDS, sepsis or septic shock) according to the recommended guidelines."}

PMC:7035340 / 2831-4000 JSONTXT

Annnotations TAB JSON ListView MergeView

PMC:7035340 / 2831-4000 JSON TXT